# Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

> **NCT01956669** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 57 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01956669
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-08
- **Primary completion:** 2019-11-05
- **Final completion:** 2019-11-05
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2020-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01956669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01956669, "Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01956669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*